

Charlotte HÃ¸ybye

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/675558/publications.pdf>

Version: 2024-02-01

85
papers

2,430
citations

196777

29
h-index

263392

45
g-index

85
all docs

85
docs citations

85
times ranked

2285
citing authors

#	ARTICLE	IF	CITATIONS
1	Natural history and surgical outcome of Rathke's cleft cystsâ€”A study from the Swedish Pituitary Registry. <i>Clinical Endocrinology</i> , 2022, 96, 54-61.	1.2	7
2	Long-term outcomes of patients with acromegaly: a report from the Swedish Pituitary Register. <i>European Journal of Endocrinology</i> , 2022, 186, 329-339.	1.9	12
3	Approach to the Patient With Praderâ€”Willi Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1698-1705.	1.8	10
4	Increased Mortality Persists after Treatment of Cushingâ€™s Disease: A Matched Nationwide Cohort Study. <i>Journal of the Endocrine Society</i> , 2022, 6, bvac045.	0.1	4
5	Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX Mutations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1183-e1194.	1.8	48
6	Simplified and improved fluid deprivation test for diagnosing diabetes insipidus. <i>European Journal of Endocrinology</i> , 2021, 184, 123-131.	1.9	8
7	Psychotropic Drugs in Patients with Cushingâ€™s Disease Before Diagnosis and at Long-Term Follow-Up: A Nationwide Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1750-1760.	1.8	15
8	Time for a general approval of growth hormone treatment in adults with Praderâ€”Willi syndrome. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 69.	1.2	13
9	ESE audit on management of adult growth hormone deficiency in clinical practice. <i>European Journal of Endocrinology</i> , 2021, 184, 323-334.	1.9	14
10	Praderâ€”Willi Syndrome and Hypogonadism: A Review Article. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2705.	1.8	29
11	Safety and effectiveness of replacement with biosimilar growth hormone in adults with growth hormone deficiency: results from an international, post-marketing surveillance study (PÄTRO Adults). <i>Pituitary</i> , 2021, 24, 622-629.	1.6	0
12	Pregnancy outcomes in women receiving growth hormone replacement therapy enrolled in the NordiNet® International Outcome Study (IOS) and the American Norditropin® Studies: Web-Enabled Research (ANSWER) Program. <i>Pituitary</i> , 2021, 24, 611-621.	1.6	7
13	Endocrine disorders in Prader-Willi syndrome: a model to understand and treat hypothalamic dysfunction. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 235-246.	5.5	80
14	Pituitary Apoplexy: A Retrospective Study of 33 Cases From a Single Center. <i>Frontiers in Endocrinology</i> , 2021, 12, 656950.	1.5	12
15	Prevalence of Nelsonâ€™s syndrome after bilateral adrenalectomy in patients with cushingâ€™s disease: a systematic review and meta-analysis. <i>Pituitary</i> , 2021, 24, 797-809.	1.6	9
16	An Adapted Model for Transition to Adult Care in Young Adults with Praderâ€”Willi Syndrome. <i>Journal of Clinical Medicine</i> , 2021, 10, 1991.	1.0	3
17	Design of the ForesiGHt Trial: A Multicenter, Randomized, Placebo- and Active-Controlled Trial to Compare Once-Weekly TransCon hGH (lonapegsomatropin) to Placebo and Daily Somatropin in Adults With Growth Hormone Deficiency (GHD). <i>Journal of the Endocrine Society</i> , 2021, 5, A519-A520.	0.1	1
18	Effects of Growth Hormone Treatment on Sleep-Related Parameters in Adults With Prader-Willi Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3634-e3643.	1.8	13

#	ARTICLE	IF	CITATIONS
19	Twenty Years of GH Treatment in Adults with Prader-Willi Syndrome. <i>Journal of Clinical Medicine</i> , 2021, 10, 2667.	1.0	6
20	Electrolyte and acid-base imbalance in severe COVID-19. <i>Endocrine Connections</i> , 2021, 10, 805-814.	0.8	22
21	Hyponatremia in Children and Adults with Prader-Willi Syndrome: A Survey Involving Seven Countries. <i>Journal of Clinical Medicine</i> , 2021, 10, 3555.	1.0	4
22	Hyperprolactinemia in Adults with Prader-Willi Syndrome. <i>Journal of Clinical Medicine</i> , 2021, 10, 3613.	1.0	4
23	Hypogonadism in Adult Males with Prader-Willi Syndrome—Clinical Recommendations Based on a Dutch Cohort Study, Review of the Literature and an International Expert Panel Discussion. <i>Journal of Clinical Medicine</i> , 2021, 10, 4361.	1.0	16
24	Safety and Effectiveness of Recombinant Human Growth Hormone in Children with Turner Syndrome: Data from the PATRO Children Study. <i>Hormone Research in Paediatrics</i> , 2021, 94, 133-143.	0.8	6
25	Hypogonadism in Women with Prader-Willi Syndrome—Clinical Recommendations Based on a Dutch Cohort Study, Review of the Literature and an International Expert Panel Discussion. <i>Journal of Clinical Medicine</i> , 2021, 10, 5781.	1.0	12
26	Growth hormone replacement in adults: Real-world data from two large studies in US and Europe. <i>Growth Hormone and IGF Research</i> , 2020, 50, 71-82.	0.5	8
27	Malignancy risk in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatotropin (Omnitrope [®]): data from the PATRO Adults study. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2020, 11, 204201882094337.	1.4	6
28	Hair cortisol—a method to detect chronic cortisol levels in patients with Prader-Willi syndrome. <i>BMC Endocrine Disorders</i> , 2020, 20, 166.	0.9	5
29	Safety of current recombinant human growth hormone treatments for adults with growth hormone deficiency and unmet needs. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1539-1548.	1.0	11
30	Residual Corticosteroid Production in Autoimmune Addison Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2430-2441.	1.8	18
31	Ten years with biosimilar rhGH in clinical practice in Sweden — experience from the prospective PATRO children and adult studies. <i>BMC Endocrine Disorders</i> , 2020, 20, 55.	0.9	8
32	Central Adrenal Insufficiency Is Rare in Adults With Prader-Willi Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2563-e2571.	1.8	27
33	Excess Morbidity Persists in Patients With Cushing's Disease During Long-term Remission: A Swedish Nationwide Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2616-2624.	1.8	42
34	Reference intervals of salivary cortisol and cortisone and their diagnostic accuracy in Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2020, 182, 569-582.	1.9	29
35	SUN-308 Central Adrenal Insufficiency Is Rare in Adults with Prader-Willi Syndrome. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.1	0
36	Letter regarding "Prevalence of growth hormone deficiency in previously GH-treated young adults with Prader-Willi syndrome" by Donze et al. <i>Clinical Endocrinology</i> , 2019, 91, 578-579.	1.2	5

#	ARTICLE	IF	CITATIONS
37	Evaluation of different hydrocortisone treatment strategies in transsphenoidal pituitary surgery. <i>Acta Neurochirurgica</i> , 2019, 161, 1715-1721.	0.9	7
38	Overall and Disease-Specific Mortality in Patients With Cushing Disease: A Swedish Nationwide Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2375-2384.	1.8	83
39	The incidence of Cushing's disease: a nationwide Swedish study. <i>Pituitary</i> , 2019, 22, 179-186.	1.6	46
40	No increased risk of glucose metabolism disorders in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope®): data from an observational, longitudinal study. <i>BMC Endocrine Disorders</i> , 2019, 19, 138.	0.9	9
41	Serum soluble urokinase plasminogen activator receptor (suPAR) in adults with growth hormone deficiency. <i>Endocrine Connections</i> , 2019, 8, 772-779.	0.8	3
42	Change in baseline characteristics over 20 years of adults with growth hormone (GH) deficiency on GH replacement therapy. <i>European Journal of Endocrinology</i> , 2019, 181, 629-638.	1.9	9
43	SAT-437 The Patro Adults Study of Omnitrope® for the Treatment of Adult Patients with Growth Hormone Deficiency: Latest Safety Outcomes Including Diabetes Risk. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.1	0
44	Temporal relationship of sleep apnea and acromegaly: a nationwide study. <i>Endocrine</i> , 2018, 62, 456-463.	1.1	17
45	The effect of time on cognitive impairments after non-traumatic subarachnoid haemorrhage and after traumatic brain injury. <i>Brain Injury</i> , 2018, 32, 1465-1476.	0.6	12
46	A phase 2 trial of long-acting TransCon growth hormone in adult GH deficiency. <i>Endocrine Connections</i> , 2017, 6, 129-138.	0.8	24
47	Is <sc>GH</sc> dosing optimal in female patients with adult-onset <sc>GH</sc> deficiency? An analysis from the NordiNet^{Å®} International Outcome Study. <i>Clinical Endocrinology</i> , 2017, 86, 798-805.	1.2	3
48	The effect of growth hormone (<sc>GH</sc>) replacement on blood glucose homeostasis in adult nondiabetic patients with <sc>GH</sc> deficiency: real-life data from the NordiNet^{Å®} International Outcome Study. <i>Clinical Endocrinology</i> , 2017, 86, 192-198.	1.2	32
49	Frequency of Cushing's syndrome due to ACTH-secreting adrenal medullary lesions: a retrospective study over 10 years from a single center. <i>Endocrine</i> , 2017, 55, 296-302.	1.1	30
50	Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations. <i>European Journal of Endocrinology</i> , 2016, 174, C1-C8.	1.9	99
51	Clinical aspects of symptomatic hyponatremia. <i>Endocrine Connections</i> , 2016, 5, R35-R43.	0.8	11
52	Bridging the gap: metabolic and endocrine care of patients during transition. <i>Endocrine Connections</i> , 2016, 5, R44-R54.	0.8	38
53	Reversible Albumin-Binding GH Possesses a Potential Once-Weekly Treatment Profile in Adult Growth Hormone Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 988-998.	1.8	24
54	Circulating maternal cortisol levels during vaginal delivery and elective cesarean section. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 267-271.	0.8	33

#	ARTICLE	IF	CITATIONS
55	Circulating Hcpidin-25 Is Reduced by Endogenous Estrogen in Humans. PLoS ONE, 2016, 11, e0148802.	1.1	56
56	Growth hormone treatment of Prader-Willi syndrome has long-term, positive effects on body composition. Acta Paediatrica, International Journal of Paediatrics, 2015, 104, 422-427.	0.7	37
57	Status of long-acting-growth hormone preparations – 2015. Growth Hormone and IGF Research, 2015, 25, 201-206.	0.5	61
58	Growth hormone replacement in adults – current standards and new perspectives. Best Practice and Research in Clinical Endocrinology and Metabolism, 2015, 29, 115-123.	2.2	30
59	Metabolomics: a tool for the diagnosis of GH deficiency and for monitoring GH replacement?. Endocrine Connections, 2014, 3, 200-206.	0.8	17
60	Glucose homeostasis in adults with Prader-Willi syndrome during treatment with growth hormone: Results from a 12-month prospective study. Growth Hormone and IGF Research, 2014, 24, 16-21.	0.5	16
61	Long-Acting Growth Hormone. Paediatric Drugs, 2013, 15, 427-429.	1.3	8
62	Current status of growth hormone therapy in Prader-Willi syndrome. Expert Review of Endocrinology and Metabolism, 2013, 8, 529-536.	1.2	1
63	Growth Hormone Research Society Workshop Summary: Consensus Guidelines for Recombinant Human Growth Hormone Therapy in Prader-Willi Syndrome. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1072-E1087.	1.8	288
64	Improved Insulin Sensitivity during Pioglitazone Treatment Is Associated with Changes in IGF-I and Cortisol Secretion in Type 2 Diabetes and Impaired Glucose Tolerance. Isrn Endocrinology, 2013, 2013, 1-9.	2.0	5
65	The NordiNet® International Outcome Study and NovoNet® ANSWER Program®: rationale, design, and methodology of two international pharmacoepidemiological registry-based studies monitoring long-term clinical and safety outcomes of growth hormone therapy (Norditropin®). Clinical Epidemiology, 2013, 5, 119.	1.5	40
66	Growth hormone treatment in adults with Prader-Willi syndrome: the Scandinavian study. Endocrine, 2012, 41, 191-199.	1.1	41
67	Growth hormone treatment for two years is safe and effective in adults with Prader-Willi syndrome. Growth Hormone and IGF Research, 2011, 21, 185-190.	0.5	37
68	Clinical features of GH deficiency and effects of 3 years of GH replacement in adults with controlled Cushing's disease. European Journal of Endocrinology, 2010, 162, 677-684.	1.9	27
69	One Year of Growth Hormone Treatment in Adults with Prader-Willi Syndrome Improves Body Composition: Results from a Randomized, Placebo-Controlled Study. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4943-4950.	1.8	53
70	Body composition, endocrine and metabolic profiles in adults with Prader-Willi syndrome. Growth Hormone and IGF Research, 2010, 20, 179-184.	0.5	60
71	Adjuvant Gamma Knife radiosurgery in non-functioning pituitary adenomas; low risk of long-term complications in selected patients. Pituitary, 2009, 12, 211-216.	1.6	52
72	Nonfatal Stroke, Cardiac Disease, and Diabetes Mellitus in Hypopituitary Patients on Hormone Replacement Including Growth Hormone. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3560-3567.	1.8	44

#	ARTICLE	IF	CITATIONS
73	Impact of the primary aetiology upon the clinical outcome of adults with childhood-onset GH deficiency. <i>European Journal of Endocrinology</i> , 2007, 157, 589-596.	1.9	18
74	Eating Behavior and Gastric Emptying in Adults with Prader-Willi Syndrome. <i>Annals of Nutrition and Metabolism</i> , 2007, 51, 264-269.	1.0	14
75	Five-years growth hormone (GH) treatment in adults with Prader-Willi syndrome. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2007, 96, 410-413.	0.7	43
76	Fracture Incidence in GH-Deficient Patients on Complete Hormone Replacement Including GH. <i>Journal of Bone and Mineral Research</i> , 2007, 22, 1842-1850.	3.1	60
77	Inflammatory Markers in Adults with Prader-Willi Syndrome before and during 12 Months Growth Hormone Treatment. <i>Hormone Research in Paediatrics</i> , 2006, 66, 27-32.	0.8	14
78	Growth hormone induced lipolysis during short- and long-term administration in adult Prader-Willi patients. <i>Growth Hormone and IGF Research</i> , 2005, 15, 411-415.	0.5	6
79	Transsphenoidal surgery in Cushing disease: 10 years of experience in 34 consecutive cases. <i>Journal of Neurosurgery</i> , 2004, 100, 634-638.	0.9	41
80	Serum adiponectin levels in adults with Prader-Willi syndrome are independent of anthropometrical parameters and do not change with GH treatment. <i>European Journal of Endocrinology</i> , 2004, 151, 457-461.	1.9	49
81	Somatropin Therapy in Adults with Prader-Willi Syndrome. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2004, 3, 153-160.	1.8	9
82	Endocrine and metabolic aspects of adult Prader-Willi syndrome with special emphasis on the effect of growth hormone treatment. <i>Growth Hormone and IGF Research</i> , 2004, 14, 1-15.	0.5	92
83	The growth hormone-insulin-like growth factor axis in adult patients with Prader-Willi syndrome. <i>Growth Hormone and IGF Research</i> , 2003, 13, 269-274.	0.5	32
84	Peptides associated with hyperphagia in adults with Prader-Willi syndrome before and during GH treatment. <i>Growth Hormone and IGF Research</i> , 2003, 13, 322-327.	0.5	56
85	Metabolic Profile and Body Composition in Adults with Prader-Willi Syndrome and Severe Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3590-3597.	1.8	129